Abstract
Objective — to improve treatment outcomes for patients with highly differentiated papillary thyroid microcarcinoma (PTMC) by developing a differentiated surgical approach based on the preoperative assessment of cytokeratin-17 (CK17) and thyroid peroxidase (TPO) expression levels in fine-needle aspiration (FNA) samples of the thyroid gland. Materials and methods. The study included 31 patients with cytologically confirmed PTMC (≤ 10 mm) without signs of autoimmune thyroiditis or metastases. All patients underwent immunocytochemical analysis of thyroid FNA samples to evaluate CK17 and TPO expression levels. Based on the results, patients were stratified into two groups: those with an aggressive tumor phenotype (CK17 ≥ 10%, TPO <25%) and those with a non-aggressive phenotype. Accordingly, patients underwent either total thyroidectomy with lymph node dissection or hemithyroidectomy. Results. In 7 (22.6%) patients, an aggressive immunocytochemical profile was established, which correlated with the detection of follicular-infiltrative or diffuse sclerotic variant of MVP according to histological analysis. The remaining patients were diagnosed with non-aggressive morphological variants (classical, varicose). No recurrence or progression of the disease was recorded during follow-up. A statistically significant (p<0.05) association between high expression of CK-17, decreased TPO levels and aggressive course of MVP was established. Conclusions. Immunocytochemical assessment of the expression of CC-17 and TPO is informative for stratifying the risk of MVP aggressiveness at the preoperative stage. The use of these markers makes it possible to individualise the scope of surgical intervention in accordance with the biological behaviour of the tumour, which is consistent with current recommendations (ATA 2023, NCCN 2024, WHO 2022).

This publication has 7 references indexed in Scilit: